All In Biotech

NDA 200740 · Leadiant Biosci INC

Cystaran

Cysteamine Hydrochloride · Ophthalmic

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 2, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

8 Phase 3, 2 recruiting

FAERS reports

458

96 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 21, 2026.

CYSTARAN ® is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. ( 1 )

Mechanism: Cysteamine acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CYSTARAN · CYSTEAMINE HYDROCHLORIDE EQ 0.44% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cysteamine" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation141
  • eye pain59
  • ocular hyperaemia54
  • photophobia36
  • product dose omission issue19
  • headache18
  • nausea17
  • vomiting17
  • intentional product misuse13
  • vision blurred13
  • burning sensation11
  • eye pruritus10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
201412
20157
201635
201774
201862
201970
202083
20216
202223
202325
202428
202531
20261

Recalls

3 FDA enforcement reports for this application.

  • Sep 24, 2020 · Class III · Terminated

    Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.

  • Apr 9, 2018 · Class III · Terminated

    Subpotent drug: Out of specification for an active ingredient cysteamine hydrochloride.

  • Feb 14, 2018 · Class III · Terminated

    Subpotent Drug: Out of specification for an active ingredient cysteamine hydrochloride.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cystaran (Cysteamine HCl)

2024 spending

$2.1M

Beneficiaries

24

242 claims

Per beneficiary

$87,118

$145.65 per unit

View as table
YearSpending
2020$2,425,528
2021$0
2022$956,416
2023$2,015,519
2024$2,090,835

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Leadiant Biosci INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.